Atai Life Sciences N.V. (ATAI)

1.0950 -0.0050 (-0.45%) As of 01:44PM EDT. Market open.

Atai Life Sciences N.V.

Wallstrasse 16
Berlin 10179
Germany
49 89 2153 9035
https://www.atai.life

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 83

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Christian Angermayer	Founder & Chairman of the Supervisory Board	70k	N/A	1978
Dr. Srinivas G. Rao M.D., Ph.D.	Co-Founder & Co-CEO	793.65k	N/A	1969
Mr. Florian Brand	Co-Founder, MD & Co-CEO	793.33k	N/A	1987
Ms. Anne Johnson	Chief Financial Officer	494.23k	N/A	1969
Dr. Michael Raven Ph.D.	Senior Vice President of Operations	N/A	N/A	N/A
Mr. Frank Stegert	Vice President of Investment & Venture Management	N/A	N/A	1981
Mr. Ryan Barrett	Senior VP, General Counsel & Corporate Secretary	N/A	N/A	1981
Dr. Glenn Short Ph.D.	Senior Vice President of Early Development	N/A	N/A	N/A
Dr. Sahil V. Kirpekar M.D.	Chief Business Officer	N/A	N/A	1986
Dr. Kevin Craig M.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Corporate Governance

Atai Life Sciences N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.